Asenapine: Efficacy and safety of 5 and 10 mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder
详细信息 查看全文
- 作者：Ronald L. Landblooma ; Mary Macklea ; Xiao Wub ; Linda Kellya ; Linda Snow-Adamia ; Roger S. McIntyrec ; Maju Mathewsb ; 1 ; Carla Hundtb ; carlahundt@msn.com" class="auth_mail" title="E-mail the corresponding author
- 关键词：AE ; adverse event ; AIMS ; Abnormal Involuntary Movement Scale ; ANCOVA ; analysis of covariance ; ATS ; all-treated set ; BARS ; Barnes Akathisia Rating Scale ; BID ; twice daily ; CGI-BP-S ; Clinical Global Impression Scale-Bipolar Illness-Severity ; CI ; confidence interval ; C-SSRS ; Columbia Suicide Severity Rating Scale ; DSM-IV ; Diagnostic and Statistical Manual of Mental Disorders ; Fourth Edition ; EPS ; extrapyramidal symptoms ; FU ; follow-up ; LS ; least-squares ; MADRS ; Montgomery&ndash ; Å ; sberg Depress
- 刊名：Journal of Affective Disorders
- 出版年：2016
- 出版时间：15 January 2016
- 年：2016
- 卷：190
- 期：Complete
- 页码：103-110
- 全文大小：815 K
文摘
- •
Fixed-dose asenapine (ASN) 5 mg bid, ASN 10 mg bid, and placebo were evaluated.
- •
Patients suffered from a mixed/manic episode associated with bipolar I disorder.
- •
Both ASN doses showed similar efficacy in improving manic and depressive symptoms.
- •
ASN 5 mg bid was associated with fewer adverse events than the 10 mg bid dose.